HC Wainwright & Co. Maintains Buy on Kiora Pharmaceuticals, Raises Price Target to $3.5
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Yi Chen maintains a 'Buy' rating on Kiora Pharmaceuticals (NASDAQ:KPRX) and raises the price target from $2 to $3.5.
November 06, 2023 | 11:42 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
The 'Buy' rating maintained by HC Wainwright & Co. and the raised price target could potentially lead to an increase in Kiora Pharmaceuticals' stock price.
Analyst ratings and price targets can significantly influence investor sentiment and stock prices. The maintained 'Buy' rating and increased price target suggest that the analyst sees potential growth in Kiora Pharmaceuticals, which could lead to increased investor interest and a potential rise in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100